Trial Profile

Phase I, Open-Label, Two Parts Study in Chinese Patients With Advanced NSCLC Who Have Progressed Following Prior Therapy With an EGFR Tyrosine Kinase Inhibitor Agent

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary)
Indications Non-small cell lung cancer
Focus Pharmacokinetics
Acronyms AURAChinaPK
Sponsors AstraZeneca

Most Recent Events

12 Nov 2019 Status changed from active, no longer recruiting to completed.
30 Jan 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
18 Jan 2018 Planned End Date changed from 29 Dec 2017 to 31 Dec 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com